Sanofi terminates deal to exclusively license Maze Therapeutics Pompe disease drug
Sanofi Genzyme goes to Phase III with Neuromuscular Disease
BioCentury - Aug. 6 Quick Takes: Sanofi gains FDA approval for Pompe therapy
Alaa Hamed, MD, MPH, MBA on LinkedIn: #wms2023 #pompe
Sanofi stock rises on licensing deal with Maze for Pompe disease drug | Seeking Alpha
Sanofi Aventis – GM IMPIANTI
FDA approves Sanofi's Nexviazyme for Pompe disease treatment
Sanofi termina l'accordo sulla licenza del farmaco dopo le obiezioni della FTC statunitense -11 dicembre 2023 alle 22:33 | MarketScreener
Sanofi coughs up $180M to settle Pompe disease royalty payment dispute | Fierce Pharma
U.S. FDA approves another Sanofi drug for rare muscle disorder Pompe disease | Reuters
Sanofi extends its Pompe range with first Nexviazyme OK | pharmaphorum
Sanofi Launched Advanced Treatment for Pompe Disease | CCI France Taiwan
Sanofi Italia on X: "La nostra ricerca sulle malattie rare non si ferma: sono 39 le presentazioni che terremo in questi giorni al @WORLDSymposia 2022 a San Francisco. Tra queste, anche nuovi
FDA aprueba Nexviazyme® de Sanofi Genzyme, una nueva e importante opción de tratamiento para la enfermedad de Pompe
Sanofi Secures FDA Nod in Late-Onset Pompe Disease | BioSpace
Lumizyme | The Pompe Registry
FDA approves Sanofi's Nexviazyme for late-onset Pompe disease - Drug Discovery and Development
Sanofi Deepens Pompe Disease Focus with $150M Maze Partnership | BioSpace
Sanofi drops acquisition of Maze's Pompe Disease drug after FTC challenge - PharmaLive
Sanofi pumps up its Pompe portfolio with Maze deal | Evaluate
Sanofi's enzyme replacement therapy available on NHS to Pompe disease patients - PMLiVE
Sanofi Genzyme: COMET Phase 3 Trial - Results | Pompe Support Network
